Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Tumor Lysis Syndrome 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia 2Hyperuricemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1HIV Infections 1Burkitt Lymphoma 1Acquired Immunodeficiency Syndrome 1

Interventions

Cytarabine 68Cyclophosphamide 44Methotrexate 41Daunorubicin 38Etoposide 34Vincristine 30Mercaptopurine 28Dexamethasone 24Radiotherapy 22Idarubicin 22Asparaginase 21Thioguanine 20Doxorubicin 19Prednisone 17Peripheral Blood Stem Cell Transplantation 17Imatinib Mesylate 16Busulfan 16pegaspargase 15Mitoxantrone 15Filgrastim 13Leucovorin 11fludarabine phosphate 10Hydrocortisone 10nilotinib 9Tretinoin 8Prednisolone 8Cyclosporine 8Hydroxyurea 7Epoetin Alfa 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leukemia × Allopurinol × Clear all
NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡